文献速递泌尿男性生殖肿瘤

前列腺癌靶向α治疗研究进展

Advances in targeted alpha therapy for prostate cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

本文综述靶向α治疗(TαT)在前列腺癌中的历史、进展与未来潜力,涵盖剂量学个体化治疗规划、联合小分子药物及靶向前列腺特异性膜抗原(PSMA)或肿瘤微环境的偶联物。III期ALSYMPCA试验中镭-223改善骨转移去势抵抗性前列腺癌总生存且长期安全耐受,PSMA靶向锕-225与钍-227偶联物正在研究中。

要点

  • 镭-223在III期ALSYMPCA试验中改善骨转移去势抵抗性前列腺癌总生存且长期安全耐受。
  • 剂量学计算与药代动力学测量支持TαT个体化治疗规划。
  • PSMA靶向锕-225与钍-227偶联物及联合化疗、雄激素受体靶向药、DNA修复抑制剂和免疫肿瘤药物正在研究。

核心结论

  • TαT在前列腺癌治疗中占据重要新角色,镭-223已提供临床概念验证,PSMA靶向TαT是 promising 治疗方向。

研究设计与样本

  • 综述,讨论TαT在前列腺癌治疗中的历史、进展与未来潜力,包括剂量学个体化治疗规划、联合小分子药物及靶向PSMA或肿瘤微环境的偶联物。

主要发现

  • III期ALSYMPCA试验显示镭-223改善骨转移去势抵抗性前列腺癌总生存,并具有长期安全性与耐受性。
  • TαT的剂量学计算与药代动力学测量为精准医学癌症管理范式下的优化和个体化治疗规划提供潜力。
  • PSMA靶向的锕-225与钍-227偶联物正在研究中。

关键数值与推荐

  • 镭-223在III期ALSYMPCA试验中改善骨转移去势抵抗性前列腺癌的总生存,并显示长期安全/耐受性。

临床怎么用

  • 基于剂量学计算和药代动力学测量优化TαT个体化治疗规划。
  • 关注PSMA靶向TαT及与化疗、雄激素受体靶向药、DNA修复抑制剂和免疫肿瘤药物的联合研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity. In this review, we discuss the history, progress, and future potential of TαT in the treatment of prostate cancer, including dosimetry-individualized treatment planning, combinations with small-molecule therapies, and conjugation to molecules directed against antigens expressed by prostate cancer cells, such as prostate-specific membrane antigen (PSMA) or components of the tumor microenvironment. A clinical proof of concept that TαT is efficacious in treating bone-metastatic castration-resistant prostate cancer has been demonstrated by radium-223 via improved overall survival and long-term safety/tolerability in the phase III ALSYMPCA trial. Dosimetry calculation and pharmacokinetic measurements of TαT provide the potential for optimization and individualized treatment planning for a precision medicine-based cancer management paradigm. The ability to combine TαTs with other agents, including chemotherapy, androgen receptor-targeting agents, DNA repair inhibitors, and immuno-oncology agents, is under investigation. Currently, TαTs that specifically target prostate cancer cells expressing PSMA represents a promising therapeutic approach. Both PSMA-targeted actinium-225 and thorium-227 conjugates are under investigation. The described clinical benefit, safety and tolerability of radium-223 and the recent progress in TαT trial development suggest that TαT occupies an important new role in prostate cancer treatment. Ongoing studies with newer dosimetry methods, PSMA targeting, and novel approaches to combination therapies should expand the utility of TαT in prostate cancer treatment.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. De Vincentis G, Gerritsen W, Gschwend JE, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019. PMID: 31418764. doi:10.1093/annonc/mdz270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。